OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

← catalyst calendar

NCT06355934 · readout in 74 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

52,121estimated

Sites

Countries

Canada, China, Denmark +8

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-08-21

actual

When the study began enrolling

Primary completion

2026-11-02

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-11-02

estimated

The whole study's end, after follow-up

First posted

2024-04-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

ATTR Amyloidosis

Intervention

Other: no intervention

Primary outcomes

what the primary-completion date above is the date OF

Health Care Resource Utilization (HCRU) - Outpatient visits

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Health Care Resource Utilization (HCRU) - Outpatient visits by specialty

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Health Care Resource Utilization (HCRU) - Emergency department visits

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Health Care Resource Utilization (HCRU) - Hospitalizations, length of stay

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Health Care Resource Utilization (HCRU) - Hospitalizations

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Health Care Resource Utilization (HCRU) - Health care cost

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Cardiac transplant

measured From diagnosis of ATTR amyloidosis (index date) until date of first cardiac transplant, assessed throughout the study until end of follow-up, up to a maximum of 12 years

All cause mortality

measured From diagnosis of ATTR amyloidosis (index date) until date of death due to any cause, assessed throughout the study until end of follow-up, up to a maximum of 12 years

Liver transplant

measured From diagnosis of ATTR amyloidosis (index date) until date of first liver transplant, assessed throughout the study until end of follow-up, up to a maximum of 12 years

Heart Failure Hospitalization

measured From diagnosis of ATTR amyloidosis (index date) until date of first hospitalization for heart failure, assessed throughout the study until end of follow-up, up to a maximum of 12 years

New ATTR amyloidosis clinical manifestation

measured From diagnosis of ATTR amyloidosis (index date) until date of first diagnosis of new ATTR amyloidosis clinical manifestation, assessed throughout the study until end of follow-up, up to a maximum of 12 years

Hospitalization (any cause)

measured From diagnosis of ATTR amyloidosis (index date) until date of first hospitalization for any reason, assessed throughout the study until end of follow-up, up to a maximum of 12 years

Neuropathy Impairment Score (NIS)

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Neuropathy Impairment Score Lower Limbs (NIS-LL)

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Neuropathy Impairment Score +7 (NIS+7)

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Neuropathy Impairment Score modified +7 (mNIS+7)

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Neuropathy symptoms and change (NCS) score

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

PND (Polyneuropathy Disability)

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Other relevant clinical measurement of ATTR amyloidosis functional status

measured From diagnosis of ATTR amyloidosis (index date), assessed throughout the study until end of follow-up, up to a maximum of 12 years

Publications

PMID 42201638 — linked by the registry
PMID 40108078 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed